1. Home
  2. KALV vs LAES Comparison

KALV vs LAES Comparison

Compare KALV & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$15.48

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$3.00

Market Cap

821.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
LAES
Founded
N/A
2022
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
821.2M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
KALV
LAES
Price
$15.48
$3.00
Analyst Decision
Strong Buy
Buy
Analyst Count
5
1
Target Price
$30.00
$7.00
AVG Volume (30 Days)
721.4K
5.6M
Earning Date
03-25-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
N/A
$64.88
Revenue Next Year
N/A
$94.93
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$2.12
52 Week High
$19.00
$8.71

Technical Indicators

Market Signals
Indicator
KALV
LAES
Relative Strength Index (RSI) 45.58 29.18
Support Level $14.59 $2.54
Resistance Level $16.49 $4.41
Average True Range (ATR) 0.98 0.27
MACD -0.06 -0.10
Stochastic Oscillator 13.35 2.90

Price Performance

Historical Comparison
KALV
LAES

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

Share on Social Networks: